



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/525,105	10/25/2005	Takafumi Ishii	62936 (46342)	2820
21874	7590	10/04/2007	EXAMINER	
EDWARDS ANGELL PALMER & DODGE LLP			YAO, LEI	
P.O. BOX 55874			ART UNIT	PAPER NUMBER
BOSTON, MA 02205			1642	
			MAIL DATE	DELIVERY MODE
			10/04/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	Application No. 10/525,105	Applicant(s) ISHII ET AL.	
	Examiner Lei Yao, Ph.D.	Art Unit 1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 25 October 2005.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-14, 17, 18, 21, 24, 25, 28, 29, 31, 32, 37-40, 42, 43, 46, 47 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) See Continuation Sheet are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |   |
|--|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)                                | / | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       |   | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ |   | 6) <input type="checkbox"/> Other: _____  |

Continuation of Disposition of Claims: Claims subject to restriction and/or election requirement are 1-14, 17, 18, 21, 24, 25, 28, 29, 31, 32, 37-40, 42, 43, 46, 47.

Art Unit: 1642

## DETAILED ACTION

### *Election/Restrictions*

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group 1, claim(s) 1-3, 11, 40, drawn to a protein or its partial peptide or pharmaceutical composition comprising the protein or peptide or a kit for screening a therapeutic agent of a cancer comprising the protein or partial peptide.

Group 2, claim(s) 4-10, 12, 13, 17-18, 25, 28-29, 43, drawn to a polynucleotide, antisense polynucleotide that is complementary to the polynucleotide, vector, transformant, pharmaceutical composition, diagnostic agent, a kit comprising the polynucleotide.

Group 3, claim(s) 14, 31-32, drawn to an antibody to a protein.

Group 4, claim(s) 21, 39, drawn to a method of screening a compound for inhibiting the activity of the protein.

Group 5, claim(s) 24, 42, drawn to a method of screening a compound for inhibiting the expression of polynucleotide.

Group 6, claim(s) 37, drawn to a therapeutic agent for a cancer, comprising a compound to inhibit the activity of a protein.

Group 7, claim(s) 38, drawn to a therapeutic agent for a cancer, comprising a compound to inhibit the expression of a gene.

Group 8, claim(s) 46-47, drawn to a method of screening an apoptosis promoter.

A national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept. When claims to different categories are present in the application, the claims will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories: (1) A product and a process specially adapted for the manufacture of said product; or (2) A product and a process of use of said product; or (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or (4) A process and an apparatus or means specifically designed for carrying out the said process; or (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process. If multiple products, processes of manufacture or uses are claimed, the first invention of the category first mentioned in the claims of the application will be considered as the main invention in the claims, see PCT article 17(3) (a) and 1.476 (c), 37 C.F.R. 1.475(b) and (d). Group I will be the main invention. After that, all other products and methods will be broken out as separate groups (see 37 CFR 1.475(d).)

Art Unit: 1642

According to PCT Rule 13.2, unity of invention exists only when the shared same or corresponding technical feature is a contribution over the prior art. The inventions listed as group I and II do not related to s single general invention concept because they lack the same or corresponding special technical feature. The technical feature of group I is drawn to a polypeptide or partial peptide comprising SEQ ID NO: 4, which is shown by Genebank access No. T50605 to lack novelty or inventive step (see attached). The Genebank access No. T50605 teaches a partial peptide of SEQ ID NO: 4, which is 100% identical to the peptide at position 188-560 of SEQ ID NO: 4. Therefore, the invention Group I does not make a contribution over the prior art. Because the peptide and its coding DNA is known in the art, the technical feature of the Group I and II is not a special technical feature, the unity of inventions drawn to DNA, protein, antibody (Group 1-3) is lacking.

In addition, according to PCT rule 13.2, unity of invention exists only when there is a shared same or corresponding special technical feature among the claimed inventions. All the other groupings are directed to the method of using but each group has different special technical feature, not sheared by the remaining groups. For example, Group 4 is directed to a method of screening a compound that inhibit the expression of the activity of the protein, which has the special technical feature of inhibiting the activity of the protein, not shared by any of the remaining groups. Group 5 is directed to a method of screening a compound for inhibiting the expression of a polynucleotide, which has the special technical feature of inhibiting the DNA expression, not sheared by any of the remaining groups. Group 6 or 7 is directed to therapeutic agent, as a product, for inhibiting the protein activity (group 6) or gene expression (group 7), which has the special technical feature of different functions respectively, not sheared by any of the remaining groups.

**Further election required under 35 U.S.C. 121:**

***Applicants elect any group from group 1-8, applicant is required to elect ONE single SEQ ID NO listed in the claims (SEQ ID NO: 1-28) for examination.***

This application is an internationally filed application filed under 35 U.S.C. 371 and is subject to the rules discussed under MPEP § 1850 (see the last paragraph under MPEP § 803.04, which references

Art Unit: 1642

the appropriate section for internationally filed applications) and international search and preliminary examination guidelines (ISPE). Under Markush practice for international applications, the following criteria are required:

(A) the alternatives have a common property or activity and (B) a common core structure is present; or

(C) in cases where the core structure cannot be the unifying criteria, all alternatives must belong to the same recognized class of chemical compounds, that is, that the same result will be achieved when one member of the Markush group is substituted for another.

In the instant case, for example, the protein of SEQ ID NO: 4 does not share a common core structure or activities with the other proteins comprising SEQ ID NO: 7, 15 17, etc. Therefore, the proteins do not meet the criteria for (A) and (B). Also, proteins do not meet criteria (C) because the same result is not achieved when determining a disease with expression of the protein of SEQ ID NO: 4 is substituted for the protein of SEQ ID NO: 7. Since the instant proteins do not share the same or corresponding special technical feature under the specific criteria for Markush practice, the proteins lack unity of invention and are not considered alternative species to one another. Therefore, applicant's proposed species election would be improper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitation of the allowable product claim will be considered for rejoinder. All claims directed a nonelected process invention must require all the limitation of an allowable product claim for that process invention to be rejoined.

In the event of a rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 C.F.R. 1.104. Thus, to be allowable, the rejoined claims must meet the criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not

Art Unit: 1642

commensurate in scope with an allowed product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that process claims should be amended during prosecution to require the limitation of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See M.P.E.P. 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lei Yao, Ph.D. whose telephone number is 571-272-3112. The examiner can normally be reached on 8am-6.00pm Monday-Thursday.

Any inquiry of a general nature, matching or file papers or relating to the status of this application or proceeding should be directed to Kim Downing for Art Unit 1642 whose telephone number is 571-272-0521

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shanon Foley can be reached on 571-272-0898. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Lei Yao,  
Examiner  
Art Unit 1642

LY

  
SHANON FOLEY  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600